Vivoryon Therapeutics N.V. Gives Replace on Rising Physique of Proof Validating Glutaminyl Cyclases as Promising Targets in DKD at World Congress of Nephrology
Halle (Saale) / Munich, Germany, March 28, 2026 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a scientific stage firm growing small molecule medicines for inflammatory and fibrotic problems, with a major give attention to kidney illnesses, right now introduced that new knowledge analyses from the Firm’s varoglutamstat Section 2 program have been offered on the World Congress of Nephrology (WCN) held in Yokohama, Japan, March 28-31, 2026.
“We are very pleased with the opportunity to share our consistently compelling results with world leading experts in the kidney space at WCN, the International Society of Nephrology’s flagship event,” stated Frank Weber, MD, CEO of Vivoryon. “With these new analyses we are able to deliver additional mechanistic proof points showing that inhibition of glutaminyl cyclases can effectively address the underlying molecular changes in diabetic kidney disease. The data continue to strengthen our ongoing development program dedicated to making a meaningful contribution to shaping the future of global kidney care.”
Presentation HighlightsVivoryon has totally analyzed kidney operate knowledge from the 2 impartial Section 2 research VIVIAD and VIVA-MIND, with extremely constant outcomes between the 2 research, highlighting the distinctive potential of varoglutamstat to meaningfully enhance kidney operate in sufferers with diabetes. The brand new analyses offered at WCN underscore earlier experiences exhibiting that the impact of varoglutamstat on eGFR noticed in each research was better in aged contributors with diabetes in comparison with aged contributors with out diabetes. In contributors with diabetes and decrease baseline eGFR (imply 60 mL/min/1.73m2), the impact dimension was comparable or increased than within the whole inhabitants of contributors with diabetes. Moreover, evaluation of information from a DKD mouse mannequin confirmed vital enhancements of irritation, glomerulosclerosis and kidney operate. Taken collectively, these outcomes add to the rising physique of proof exhibiting that inhibition of glutaminyl cyclases is legitimate strategy to handle the underlying inflammatory and fibrotic modifications in DKD and assist additional growth of varoglutamstat in sufferers with diabetes and extra superior CKD levels.
Presentation DetailsPresentation Date/Time: March 28, 2026, 5:00 pm JST/9:00 am CET Poster Title: Translational Validation of Glutaminyl-Cyclases as Promising New Goal for Remedy of DKD (P334)Venue: Pacifico Yokohama, Yokohama, JapanPresenter: Christine Wenzkowski, PhD, VP Enterprise Improvement of Vivoryon
More Read
###
About Vivoryon Therapeutics N.V.
Vivoryon is a scientific stage biotechnology firm targeted on growing modern small molecule-based medicines for the remedy of inflammatory and fibrotic problems of the kidney. Pushed by its ardour for ground-breaking science and innovation, the Firm strives to enhance affected person outcomes by altering the course of extreme illnesses via modulating the exercise and stability of pathologically related proteins. Vivoryon’s most superior program, varoglutamstat, a proprietary, first-in-class orally out there QPCT/L inhibitor, is being evaluated to deal with diabetic kidney illness. www.vivoryon.com
More Read
Vivoryon Ahead Trying Statements
This press launch contains forward-looking statements, together with, with out limitation, these relating to the enterprise technique, administration plans and goals for future operations of Vivoryon Therapeutics N.V. (the “Company”), estimates and projections with respect to the marketplace for the Firm’s merchandise and forecasts and statements as to when the Firm’s merchandise could also be out there. Phrases similar to “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “project,” “predict,” “should” and “will” and comparable expressions as they relate to the Firm are supposed to establish such forward-looking statements. These forward-looking statements usually are not ensures of future efficiency; relatively they’re primarily based on the Administration’s present expectations and assumptions about future occasions and tendencies, the economic system and different future situations. The forward-looking statements contain numerous recognized and unknown dangers and uncertainties. These dangers and uncertainties and different elements might materially adversely have an effect on the result and monetary results of the plans and occasions described herein. The Firm’s outcomes of operations, money wants, monetary situation, liquidity, prospects, future transactions, methods or occasions could differ materially from these expressed or implied in such forward-looking statements and from expectations. Consequently, no undue reliance ought to be positioned on such forward-looking statements. This press launch doesn’t include threat elements. Sure threat elements that will have an effect on the Firm’s future monetary outcomes are mentioned within the printed annual monetary statements of the Firm. This press launch, together with any forward-looking statements, speaks solely as of the date of this press launch. The Firm doesn’t assume any obligation to replace any info or forward-looking statements contained herein, save for any info required to be disclosed by legislation.
